Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Patients Less Than 1 Year of Age

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04188964
Recruitment Status : Recruiting
First Posted : December 6, 2019
Last Update Posted : January 31, 2022
Sponsor:
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development Ltd

Brief Summary:
A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Paediatric Patients from Birth to Less than 1 Year of Age with X-linked Hypophosphatemia (XLH)

Condition or disease Intervention/treatment Phase
X-linked Hypophosphatemia (XLH) Drug: Burosumab Phase 1 Phase 2

Detailed Description:

BUR-CL207 is a multicenter, open-label, non-randomized Phase 1/2 study in pediatric patients with XLH initiating treatment with burosumab at <12 months of age. The study includes a total treatment period of up to 48 weeks across 3 cohorts. Subjects will be enrolled in 2 age subgroups: (1) ≥6 months to <12 months of age, and (2) <6 months of age at initiation of burosumab treatment. Cohorts will aim to include 3 subjects per cohort depending on the starting dose of burosumab and relative response of patients to treatment as assessed by serum phosphate levels and by the treating physician (Investigator). Cohorts will commence in a staggered manner starting with Cohort 1, followed by Cohorts 2 and 3, which may start in parallel after an adequate observation period (4 weeks) in Cohort 1 and with approval from the Sponsor's Medical Monitor and the DSMB. The cohorts are defined as follows:

  • Cohort 1: pediatric subjects with XLH and hypophosphatemia (serum phosphate below the age-adjusted lower limit of normal [LLN]), and age from ≥6 months to <12 months of age at initiating treatment with burosumab with starting dose of 0.4 mg/kg.
  • Cohort 2: pediatric subjects with XLH and hypophosphatemia (serum phosphate below the age-adjusted LLN), and age from ≥6 months to <12 months of age at initiating treatment with burosumab with a starting dose of 0.8 mg/kg (upon Data Safety Monitoring Board [DSMB] confirmation).
  • Cohort 3: pediatric subjects with XLH and hypophosphatemia (serum phosphate below the age-adjusted LLN), and <6 months of age at initiating treatment with burosumab with a starting dose of 0.4 mg/kg (upon DSMB confirmation). Following enrollment of the first 3 or 4 subjects in Cohort 3, an interim population PK/PD evaluation may be performed to determine whether the starting dose for the cohort can be increased to 0.8 mg/kg.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1/2, Open-label, Multicenter, Non-randomized Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Burosumab in Pediatric Patients From Birth to Less Than 1 Year of Age With X-linked Hypophosphatemia (XLH)
Actual Study Start Date : February 26, 2020
Estimated Primary Completion Date : February 2023
Estimated Study Completion Date : April 2024


Arm Intervention/treatment
Experimental: Treatment
Pediatric subjects > = 6 months to < 12 months will receive a starting dose of 0.4mg/kg administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option of the dose to be increased to 0.8mg/kg upon recommendation of the Data Safety Management Board (DSMB). The dose can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response. Upon recommendation of the DSMB subjects < 6 months can then start at 0.4mg/kg starting dose administered subcutaneously (SC) every 2 weeks (Q2W) for 48 weeks with the option to be increased to 0.8mg/kg upon recommendation of the DSMB and can be either increased up to a maximum of 2 mg/kg or decreased to 0.2 mg/kg depending on serum phosphate response.
Drug: Burosumab
Burosumab is a sterile clear colourless to slightly yellow and preservative free solution supplied in single use 5ml vials containing 1 mL of Burosumab at a concentration of 10mg/mL,20 mg/mL or 30mg/mL, administered by SC injections every 2 weeks.
Other Names:
  • KRN23
  • Crysvita




Primary Outcome Measures :
  1. To assess the safety and tolerability of Burosumab in paediatric subjects with X-linked Hypophosphatemia (XLH) starting treatment below 12 months of age [ Time Frame: From Baseline to scheduled time points (measured throughout the study up to Week 48). ]
    Incidence, frequency, and severity of adverse events (AEs) and serious AEs (SAEs), including clinically significant changes in laboratory, physical examinations, vital signs, ECGs and imaging assessments


Secondary Outcome Measures :
  1. To characterize the pharmacokinetics (PK) of Burosumab following subcutaneous (SC) injection in paediatric subjects with XLH below 12 months of age. [ Time Frame: Measured throughout the study up to Week 48 ]
    Burosumab serum concentrations and PK parameters, including apparent clearance (CL/F), apparent volume of distribution (V/F), area under the serum concentration-time curve (AUC), maximum serum drug concentration (Cmax) and other parameters, as appropriate.

  2. To characterize the effect of Burosumab on serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D) in paediatric subjects with XLH starting treatment below 12 months of age [ Time Frame: Change from Baseline at Week 20, 26, 32, 40 and 48 ]
    Changes in serum phosphate and 1,25-dihydroxyvitamin D (1,25[OH]2D)

  3. To assess the clinical effects of Burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: Baseline and Week 48 ]
    Change in serum alkaline phosphatase (ALP).

  4. To assess the clinical effects of Burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    Appearance in radiographic appearance of rickets severity as assessed by the Radiograph Global Impression of Change (RGI-C) scoring system.

  5. To assess the clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    The appearance in rickets severity assessed by total Rickets Severity Score (RSS).

  6. To assess the clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    Change in lower extremity skeletal abnormalities, including genu varum and genu valgus, as determined by the RGI-C long leg score.

  7. To assess the clinical effects of burosumab on growth and prevention and/or healing of rickets and skeletal deformities [ Time Frame: At week 48 ]
    Change in recumbent length in cm, height-for-age z-scores, and percentiles.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 1 Year   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female pediatric subjects, aged <12 months at burosumab treatment initiation.
  2. Pediatric subjects with PHEX mutation or variant of uncertain significance in either the subject or a directly related family member with appropriate X-linked inheritance.
  3. Presenting serum phosphate levels below the age-specific LLN at Screening.
  4. A legally authorized representative has provided written informed consent prior to any research-related procedures.
  5. A legally authorized representative must, in the opinion of the Investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments required by the study protocol, including providing access to prior medical records for the collection of historical growth, biochemical, and radiographic data and disease history.

Exclusion Criteria:

  1. The pediatric subject's legally authorized representative is unwilling or unable to stop the subject's treatment with oral phosphate and/or pharmacologic vitamin D metabolite or analogue (e.g. calcitriol, alfacalcidol) for at least 1 week before planned treatment start and for the duration of the study.
  2. Preterm pediatric patients (defined as born before 37 weeks of pregnancy) with a chronological age of <6 months. Enrolment of preterm pediatric patients with a chronological age ≥6 months must be confirmed by the Study Medical Monitor before study entry.
  3. Impairment of renal function measured as serum creatinine above the age-adjusted normal range and estimated GFR (calculated using the Bedside Schwartz equation) below the age-adjusted normal range.
  4. Presence of nephrocalcinosis on renal ultrasound.
  5. Hypocalcemia or hypercalcemia, defined as serum calcium levels outside the age-adjusted normal limits.
  6. Presence of a concurrent disease or condition that would interfere with study participation or affect subject safety.
  7. Predisposition to infection or known immunodeficiency.
  8. Severe dermatological conditions over the available injection sites.
  9. Use of any investigational product or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
  10. Metabolic bone disease, nutritional rickets and/or osteopenia of other origin than XLH at Screening and/or Baseline.
  11. Serum levels of 25-hydroxyvitamin D (25(OH)D) below the LLN that are clinically significant in the opinion of the Investigator.
  12. Evidence of any hyperparathyroidism not associated with XLH as determined by the Investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04188964


Contacts
Layout table for location contacts
Contact: Development Division Project Management Department 609-919-1100 kkd.clintrial.82@kyowakirin.com

Locations
Layout table for location information
Austria
Kepler Universitaetsklinikum GmbH Recruiting
Linz, Austria
Contact: Wolfgang Hogler         
France
Centre de reference des maladies renales rares-Hospices Civils de Lyon-Hopital Femme Mere Enfant Recruiting
Lyon, France
Contact: Bacchetta, Prof         
Hopital Kremlin APHP Recruiting
Paris, France
Contact: Linglart, Prof         
Italy
Ospedale Pediatrico Bambino Gesù Recruiting
Rome, Italy
Contact: Emma, Prof         
Spain
Hospital Virgen del Rocío Recruiting
Sevilla, Spain
Contact: Francisco De la Cerda Ojeda       paco@delacerda.es   
Sweden
Karolinska University Hospital Recruiting
Stockholm, Sweden
Contact: Division S Project Management Department       kkd.clintrial.82@kyowakirin.com   
United Kingdom
Evelina London Children's Hospital - Guy's & St Thomas' NHS Foundation Trust Active, not recruiting
London, United Kingdom
Great Ormond Street Hospital Recruiting
London, United Kingdom
Contact: Division Project Management Department       kkd.clintrial.82@kyowakirin.com   
Royal Manchester Children's Hospital Recruiting
Manchester, United Kingdom
Contact: Division S Project Management Department       kkd.clintrial.82@kyowakirin.com   
Sponsors and Collaborators
Kyowa Kirin Pharmaceutical Development Ltd
Layout table for additonal information
Responsible Party: Kyowa Kirin Pharmaceutical Development Ltd
ClinicalTrials.gov Identifier: NCT04188964    
Other Study ID Numbers: BUR-CL207
First Posted: December 6, 2019    Key Record Dates
Last Update Posted: January 31, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Familial Hypophosphatemic Rickets
Hypophosphatemia
Phosphorus Metabolism Disorders
Metabolic Diseases
Rickets, Hypophosphatemic
Rickets
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Hypophosphatemia, Familial
Renal Tubular Transport, Inborn Errors
Kidney Diseases
Urologic Diseases
Metal Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Calcium Metabolism Disorders
Vitamin D Deficiency
Avitaminosis
Deficiency Diseases
Malnutrition
Nutrition Disorders